Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: later stage assets help fundraising; dealmaking surges this year; Amgen’s approach to AI; Takeda’s AI strategy; and Anthropic launches Claude Science.
Scrip - July 5, 2026

Medtech’s 2026 Cybersecurity Breaches Spared The Devices — And Hammered Everything Else
In 2026, medtech's cyber defenses cracked one after another — exposing an industry caught between legacy systems it cannot patch and new digital tools it hasn't secured.
Medtech Insight - July 3, 2026

FDA Classifies Insulet’s Omnipod Correction As Class I Recall Over Cannula Defect
The FDA has classified Insulet's voluntary correction of ~7 million Omnipod pods as a Class I recall over a cannula-tear defect that can cause undetected insulin under-delivery and, in severe cases, DKA. Insulet reports 24 serious adverse events, no deaths, and up to $50m in 2026 costs.
Medtech Insight - July 3, 2026

Plaintiffs Say Stimulator Makers Used FDA Supplement Pathway To Avoid New Trials
A federal panel has centralized 14 spinal cord stimulator suits against Boston Scientific in California, as plaintiffs allege manufacturers used incremental FDA supplement filings to overhaul Class III devices without new safety trials. Separate MDLs for Abbott and Nevro are planned.
Medtech Insight - July 3, 2026

‘Five Pillars’ For US Supplement GMP Compliance Are ‘No Surprise’ But Also Commonly Missed
“If we start seeing crumbling in multiple of them, that's where an investigator is going to really start digging and say, is this an issue with one product or one situation, maybe just one column, so maybe the batch production records are incomplete?” says Siobhan Gallagher Taylor in FDA’s OII.
HBW Insight - July 3, 2026

US Consumer Health Industry News Digest: Business, Regulation, Science
FTC wants AI policy statement input; CRN completes filing briefs with Supreme Court on New York law challenge; NIH announces Supplements Facts First Challenge phase 1 winners; and HBW Insight publishes article packages from AESGP meeting in Berlin and US OTC sunscreen ingredient approval.
HBW Insight - July 3, 2026

Prestige Biopharma And Charles River Align On Biosimilar Development
Prestige Biopharma and Charles River Laboratories have signed a MoU establishing a mutual client referral arrangement to accelerate biosimilar development.
Generics Bulletin - July 3, 2026

Celltrion Leads The Way In US With Interchangeable Rituximab Biosimilar??
Celltrion has strengthened its position in the US rituximab biosimilar market with the announcement of interchangeability status for its Teva-partnered Truxima version.??
Generics Bulletin - July 3, 2026

Sandoz’s Direct-to-Patient Platform Is First Step In Long-Term DTP Strategy
Sandoz has launched a “Sandoz Direct” US direct-to-patient platform, with somatropin biosimilar Omnitrope as its first product. The company told Generics Bulletin that the platform marked just the first step in building a long-term DTP capability, with further products expected to be added.
Generics Bulletin - July 3, 2026

How Western Biotechs Are Navigating The China Challenge
As the BIOSECURE Act and proposed investment-screening laws reshape competition, US biotechs debate whether to engage China's surging drug pipeline or differentiate against it, with no industry-wide consensus on the right approach.
In Vivo - July 2, 2026